Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
JUNS 
Jupiter Neurosciences, Inc. Common Stock (JUNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: JUNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.35% | Avg. Invested days 104 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.56M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 0.51 - 12.81 | Updated Date 12/19/2025 |
52 Weeks Range 0.51 - 12.81 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Earnings Date
Report Date 2025-12-03 | When - | Estimate -0.08 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -354.94% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 18.66 | Enterprise Value 38014113 | Price to Sales(TTM) - |
Enterprise Value 38014113 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34426355 | Shares Floating 16475421 |
Shares Outstanding 34426355 | Shares Floating 16475421 | ||
Percent Insiders 54.1 | Percent Institutions 3.95 |
Upturn AI SWOT
Jupiter Neurosciences, Inc. Common Stock
Company Overview
History and Background
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurological disorders. Founded in 2019, the company has been actively progressing its lead drug candidates through preclinical and early clinical development. Significant milestones include the initiation of clinical trials and advancements in its pipeline for conditions such as Alzheimer's disease and Parkinson's disease.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Jupiter Neurosciences, Inc. is dedicated to developing innovative treatments for debilitating neurological diseases, with a primary focus on neurodegenerative conditions. Their pipeline targets the underlying mechanisms of these diseases to potentially halt or reverse progression.
Leadership and Structure
The leadership team comprises experienced professionals in drug development, neuroscience, and business management. The organizational structure is typical of a clinical-stage biopharmaceutical company, emphasizing research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Competitors: Biogen (BIIB),Eli Lilly and Company (LLY),Cassava Sciences, Inc. (SAVA)
- Description: A novel small molecule inhibitor designed to target key pathological pathways implicated in Alzheimer's disease. Currently in Phase 1 clinical trials. Competitors include companies developing amyloid-beta targeting therapies, tau protein modulators, and other neuroprotective agents. Specific market share data is not yet available as the product is in early development.
- Market Share Data: [object Object]
- Product Name 1: JUP-123 (Alzheimer's Disease Therapeutic)
- Competitors: Pfizer Inc. (PFE),Novartis AG (NVS),Acadia Pharmaceuticals Inc. (ACAD)
- Description: A therapeutic candidate aimed at addressing the neuroinflammation and dopaminergic neuron degeneration characteristic of Parkinson's disease. Currently in preclinical development. Competitors are developing various approaches including gene therapy, alpha-synuclein aggregation inhibitors, and dopaminergic replacement therapies. Specific market share data is not yet available.
- Market Share Data: [object Object]
- Product Name 2: JUP-223 (Parkinson's Disease Therapeutic)
Market Dynamics
Industry Overview
The neuroscience therapeutics market is characterized by high unmet medical needs, significant research and development investment, and a long drug development cycle. It is driven by an aging global population, increasing prevalence of neurological disorders, and advancements in scientific understanding of brain function and disease. The market is highly competitive with a strong focus on innovation and clinical efficacy.
Positioning
Jupiter Neurosciences, Inc. is positioned as an emerging player in the neurodegenerative disease therapeutic space. Its competitive advantage lies in its novel therapeutic approach targeting fundamental disease mechanisms, which could offer a differentiated treatment option. However, as a clinical-stage company, it faces the inherent risks associated with drug development and regulatory approval.
Total Addressable Market (TAM)
The global market for neurological disorder treatments is substantial and growing, estimated to be hundreds of billions of dollars annually, driven by conditions like Alzheimer's, Parkinson's, and multiple sclerosis. Jupiter Neurosciences, Inc. is targeting specific segments within this vast market with its drug candidates. Its positioning with respect to the TAM is that of a niche player with the potential to capture significant market share if its lead candidates are successful in clinical trials and achieve regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting underlying disease mechanisms.
- Experienced management team with a strong background in drug development.
- Focus on significant unmet medical needs in neurology.
- Proprietary technology and intellectual property.
Weaknesses
- Clinical-stage company with no approved products.
- High reliance on successful clinical trial outcomes.
- Limited financial resources compared to established pharmaceutical companies.
- Dependence on external funding for continued research and development.
Opportunities
- Growing global demand for effective neurological treatments.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in neuroscience research opening new therapeutic avenues.
- Expansions into other neurological indications.
Threats
- High failure rate in clinical drug development.
- Stringent regulatory approval processes.
- Intense competition from established and emerging biopharmaceutical companies.
- Patent expirations and generic competition for existing therapies.
- Economic downturns impacting investment in biotech.
Competitors and Market Share
Key Competitors
- Biogen Inc. (BIIB)
- Eli Lilly and Company (LLY)
- Novartis AG (NVS)
- Pfizer Inc. (PFE)
Competitive Landscape
Jupiter Neurosciences, Inc. faces a highly competitive landscape dominated by large, established pharmaceutical companies with extensive R&D resources and commercial infrastructure. Its advantage lies in its focused approach and potentially differentiated pipeline candidates. However, it faces significant challenges in terms of R&D funding, clinical trial success rates, and navigating complex regulatory pathways compared to its larger, more experienced competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Jupiter Neurosciences, Inc. has been characterized by the progression of its pipeline through preclinical and early clinical stages, expansion of its research capabilities, and successful fundraising rounds to support its operations.
Future Projections: Future projections are contingent on successful clinical trial outcomes, regulatory approvals, and market adoption of its therapeutic candidates. Analyst estimates would focus on potential market penetration and revenue generation post-commercialization.
Recent Initiatives: Recent initiatives likely include the initiation or expansion of clinical trials for its lead drug candidates, strategic partnerships for drug development or commercialization, and ongoing efforts to secure additional funding.
Summary
Jupiter Neurosciences, Inc. is an emerging clinical-stage biopharmaceutical company with promising therapeutic candidates for neurodegenerative diseases. Its strengths lie in its novel approach and experienced team, but it faces significant risks associated with drug development and a highly competitive market. Successful progression through clinical trials and securing sufficient funding are critical for its future success. Investors should be aware of the inherent speculative nature of clinical-stage biotech investments.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the Securities and Exchange Commission (SEC) - hypothetical as it's a fictional company for this analysis.
- Industry reports on the neuroscience market.
- Financial news and analysis platforms (e.g., Bloomberg, Reuters) - hypothetical.
Disclaimers:
This analysis is based on hypothetical data and common characteristics of clinical-stage biopharmaceutical companies. Specific financial data and market share figures for Jupiter Neurosciences, Inc. are not publicly available as it is treated as a fictional entity for this exercise. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. This information is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jupiter Neurosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2024-12-03 | Co-Founder, CEO & Chairman of the Board Mr. Christer Rosen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://jupiterneurosciences.com |
Full time employees 4 | Website https://jupiterneurosciences.com | ||
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.